Skip to main content

53 publications

Name Date Type Actions

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

 

05/01/2021 Liquidity contract

Monthly information regarding the total number of voting rights and shares making of the share capital - December 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

07/01/2021 Voting rights

Programme de rachat - December 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

07/01/2021 Monthly communication regarding buyback programs

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

11/01/2021 Public releases

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

18/01/2021 Public releases

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.

21/01/2021 Public releases

Programme de rachat - January 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

04/02/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - January 2021

04/02/2021 Voting rights

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

08/02/2021 press release excluding results

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

08/02/2021 Public releases